A Long-Term Study of Prognosis in Monoclonal Gammopathy of Undetermined Significance
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
BACKGROUND: A monoclonal gammopathy of undetermined significance (MGUS) occurs in up to 2 percent of persons 50 years of age or older. Reliable predictors of progression have not been identified, and information on prognosis is limited. METHODS: We identified 1384 patients residing in southeastern Minnesota in whom MGUS was diagnosed at the Mayo Clinic from 1960 through 1994. The primary end point was progression to multiple myeloma or another plasma-cell cancer. RESULTS: During 11,009 person-years of follow-up, MGUS progressed in 115 of the 1384 patients to multiple myeloma, IgM lymphoma, primary amyloidosis, macroglobulinemia, chronic lymphocytic leukemia, or plasmacytoma (relative risk of progression, 25.0, 2.4, 8.4, 46.0, 0.9, and 8.5, respectively). The overall relative risk of progression was 7.3 in these patients as compared with the white population of the Iowa Surveillance, Epidemiology, and End Results program. In 32 additional patients, the monoclonal protein concentration increased to more than 3 g per deciliter or the percentage of plasma cells in the bone marrow increased to more than 10 percent (smoldering multiple myeloma) but without progression to overt myeloma or related disorders. The cumulative probability of progression was 12 percent at 10 years, 25 percent at 20 years, and 30 percent at 25 years. The initial concentration of serum monoclonal protein was a significant predictor of progression at 20 years. CONCLUSIONS: The risk of progression of MGUS to multiple myeloma or related disorders is about 1 percent per year.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“MGUS progresses to multiple myeloma or related malignancy a rate of 1% per year.16,17”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [16]
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Asymptotically Efficient Rank Invariant Test Procedures
Peto, R., & Peto, J. (1972) · Journal of the Royal Statistical Society. Series A (General) · doi:10.2307/2344317 · Cited by 3,393
Gooley, T. A., Leisenring, W., Crowley, J., & Storer, B. E. (1999) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19990330)18:6<695::aid-sim60>3.0.co;2-o · Cited by 2,688
History of the Rochester Epidemiology Project
Melton, L. J. (1996) · Mayo Clinic Proceedings · doi:10.4065/71.3.266 · Cited by 1,443
Self-citationKyle, R., Linos, A., Beard, C., Linke, R., Gertz, M., O'Fallon, W., & Kurland, L. (1992) · Blood · doi:10.1182/blood.v79.7.1817.1817 · Cited by 657
Self-citationMonoclonal gammopathy of undetermined significance
Kyle, R. A. (1978) · The American Journal of Medicine · doi:10.1016/0002-9343(78)90522-3 · Cited by 607
Self-citationFrequency of Pathological Proteins (M‐components) in 6,995 Sera from an Adult Population
AXELSSON, U., BACHMANN, R., & HÄLLÉN, J. (1966) · Acta Medica Scandinavica · doi:10.1111/j.0954-6820.1966.tb05453.x · Cited by 436
“Benign” Monoclonal Gammopathy—After 20 to 35 Years of Follow-Up
KYLE, R. A. (1993) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(12)60015-9 · Cited by 338
Self-citationThe Analysis of Mortality by the Subject-Years Method
Berry, G. (1983) · Biometrics · doi:10.2307/2530817 · Cited by 278
Research works printed but not linked: 4
- Hallen J, 1966, Acta Med Scand Suppl, 462, 1
- Kyle RA, Katzmann JA. Immunochemical characterization of immunoglobulins. In: Rose NR, Conway de Macario E, Folds JD, Lane HC, Nakamura RM, eds. Manual of clinical laboratory immunology. 5th ed. Washington, D.C.: ASM Press, 1997:156-76.
- Kyle RA, 1999, Blood, 94, 537a
- Fonseca R, 1999, Blood, 94, 663a
Cited by
Items 201–300 of 1,000
Morgan, G. J., & Kelly, J. W. (2016) · Journal of Molecular Biology · doi:10.1016/j.jmb.2016.08.021 · Cited by 95
“In AL amyloidosis, the population of clonal plasma cells is generally small and proteotoxicity occurs without fully-developed cancer symptoms, although amyloid deposition can also be a symptom of multiple myeloma, a more aggressive plasma cell cancer [8, 9].”
BackgroundEl-Khoury, H., Lee, D. J., Alberge, J.-B., Redd, R., Cea-Curry, C. J., Perry, J., Barr, H., Murphy, C., Sakrikar, D., Barnidge, D., et al. (2022) · The Lancet Haematology · doi:10.1016/s2352-3026(22)00069-2 · Cited by 94
PI3K/AKT/mTOR pathway in multiple myeloma: from basic biology to clinical promise
Ramakrishnan, V., & Kumar, S. (2018) · Leukemia & Lymphoma · doi:10.1080/10428194.2017.1421760 · Cited by 89
Monoclonal gammopathy related to Sjögren syndrome: A key marker of disease prognosis and outcomes
Brito‐Zerón, P., Retamozo, S., Gandía, M., Akasbi, M., Pérez-De-Lis, M., Díaz‐Lagares, C., Bosch, X., Bové, A., Pérez-Álvarez, R., Cárdenas, M. J. S., et al. (2012) · Journal of Autoimmunity · doi:10.1016/j.jaut.2012.01.010 · Cited by 93
Agarwal, A., & Ghobrial, I. M. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2922 · Cited by 106
“Type of immunoglobulin Patients withMGUSwith IgM or IgAmonoclonal protein have an increased risk of progression to disease as compared with patients with IgG protein (52).”
BackgroundPaiva, B., Vídriales, M., Rosiñol, L., Martínez‐López, J., Mateos, M., Ocio, E. M., Montalbán, M.-Á., Cordón, L., Gutierrez, N. C., Corchete, L. A., et al. (2013) · Leukemia · doi:10.1038/leu.2013.166 · Cited by 98
Paiva, B., Pérez‐Andrés, M., Vídriales, M., Almeida, J., Heras, N. D. L., Mateos, M., López‐Corral, L., Gutierrez, N. C., Blanco, J. F., Oriol, A., et al. (2011) · Leukemia · doi:10.1038/leu.2010.320 · Cited by 119
Advances in Biology and Therapy of Multiple Myeloma
Barillé-Nion, S., Barlogie, B., Bataille, R., Bergsagel, P. L., Epstein, J., Fenton, R. G., Jacobson, J., Kuehl, W. M., Shaughnessy, J., & Tricot, G. (2003) · Hematology · doi:10.1182/asheducation-2003.1.248 · Cited by 93
Rosiñol, L., Cibeira, M. T., Montoto, S., Rozman, M., Esteve, J., Filella, X., & Bladé, J. (2007) · Mayo Clinic Proceedings · doi:10.4065/82.4.428 · Cited by 98
Landgren, O. (2013) · Hematology · doi:10.1182/asheducation-2013.1.478 · Cited by 87
The malignant clone and the bone-marrow environment
Podar, K., Richardson, P. G. G., Hideshima, T., Chauhan, D., & Anderson, K. C. (2007) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2007.08.002 · Cited by 98
Imaging of multiple myeloma: Current concepts
Derlin, T., & Bannas, P. (2014) · World Journal of Orthopedics · doi:10.5312/wjo.v5.i3.272 · Cited by 98
Kristinsson, S. Y., Björkholm, M., Goldin, L. R., Blimark, C., Mellqvist, U., Wahlin, A., Turesson, I., & Landgren, O. (2009) · International Journal of Cancer · doi:10.1002/ijc.24514 · Cited by 88
“Compared to first-degree relatives of controls, we found that first-degree relatives of patients with MM had a 2-fold higher risk of developing MM.”
BackgroundInfluentialSmoldering multiple myeloma current treatment algorithms
Rajkumar, S. V., Kumar, S., Lonial, S., & Mateos, M. V. (2022) · Blood Cancer Journal · doi:10.1038/s41408-022-00719-0 · Cited by 74
Self-citationPolycomb Target Genes Are Silenced in Multiple Myeloma
Kalushkova, A., Fryknäs, M., Lemaire, M., Fristedt, C., Agarwal, P., Eriksson, M., Deleu, S., Atadja, P. W., Österborg, A., Nilsson, K., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011483 · Cited by 97
“The existence of the silenced gene expression profile in MGUS, recently proposed to precede MM in majority of the cases [46,47,48], suggests that aberrant Polycomb-mediated gene silencing might be an early event during MM development.”
BackgroundThe evolving use of serum free light chain assays in haematology
Pratt, G. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07079.x · Cited by 94
“…factors for progression identified by the Mayo group were the size and type of M protein (increased risk of progression with IgM and IgA subtypes) (Kyle et al, 2002) and, by other groups, bone marrow plasma cell percentage (Cesana et al, 2002), the presence of circulating plasma cells (Kumar et…”
BackgroundTiming of acquisition of deletion 13 in plasma cell dyscrasias is dependent on genetic context
Chiecchio, L., Dagrada, G. P., Ibrahim, A. H., Cabanas, E. D., Protheroe, R. K. M., Stockley, D. M., Orchard, K. H., Cross, N. C. P., Harrison, C. J., Ross, F. M., et al. (2009) · Haematologica · doi:10.3324/haematol.2009.011064 · Cited by 86
Systemic amyloidosis: a challenge for the rheumatologist
Perfetto, F., Pignone, A. M., Livi, R., Tempestini, A., Bergesio, F., & Matucci‐Cerinic, M. (2010) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2010.84 · Cited by 86
“In addition, since monoclonal gammopathy of unknown significance is not infrequent in elderly individuals”
BackgroundLandgren, O., Kyle, R. A., & Rajkumar, S. V. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1822 · Cited by 96
“with MGUS have a 1% annual risk of progression to multiple myeloma (MM) or related malignancy (3).”
BackgroundSelf-citationde Chambrun, M. P., Gousseff, M., Mauhin, W., Lega, J., Lambert, M., Rivière, S., Dossier, A., Ruivard, M., Lhote, F., Blaison, G., et al. (2017) · The American Journal of Medicine · doi:10.1016/j.amjmed.2017.05.023 · Cited by 86
Multiple Myeloma: Molecular Pathogenesis and Disease Evolution
Heider, M., Nickel, K., Högner, M., & Bassermann, F. C. (2021) · Oncology Research and Treatment · doi:10.1159/000520312 · Cited by 95
Baldini, L., Goldaniga, M. C., Guffanti, A., Broglia, C. M., Cortelazzo, S., Rossi, A., Morra, E., Colombi, M., Callea, V., Pogliani, E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.147 · Cited by 85
“Other updated reviews of monoclonal gammopathy suggest more definite criteria based on serum MC levels and the degree of bone marrow infiltration.(5-7) Taking these proposals into account, we analyzed a large series of patients with IgM MGUS or indolent/asymptomatic WM (IWM) in order to verify whether the two diseases…”
BackgroundMethodShimanovsky, A., Alvarez, A. J., Murali, S., & Dasanu, C. A. (2016) · BBA Clinical · doi:10.1016/j.bbacli.2016.05.004 · Cited by 85
Sallah, S., Husain, A., Wan, J. Y., Vos, P. W., & Nguyen, N. P. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh385 · Cited by 85
“Monoclonal gammopathy of undetermined significance (MGUS) is a well known condition that predisposes patients for the development of multiple myeloma, with risk approaching 25% at 20 years of follow-up [4].”
BackgroundMultiple myeloma: clinical features and indications for therapy
Dispenzieri, A. A., & Kyle, R. A. (2005) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2005.01.008 · Cited by 100
Self-citationKaufmann, H., Ackermann, J., Baldia, C., Nösslinger, T., Wieser, R., Seidl, S., Sagaster, V., Gisslinger, H., Jaeger, U., Pfeilstöcker, M., et al. (2004) · Leukemia · doi:10.1038/sj.leu.2403518 · Cited by 92
Early Genetic Events Provide the Basis for a Clinical Classification of Multiple Myeloma
Kuehl, W. M., & Bergsagel, P. L. (2005) · Hematology · doi:10.1182/asheducation-2005.1.346 · Cited by 96
“Nearly half of MM tumors are hyperdiploid (HRD) (48-75 chromosomes), and often have multiple trisomies involvi g eight odd chromosomes (3,5,7,9,11,15,19,21).”
BackgroundInherited genetic susceptibility to multiple myeloma
Morgan, G. J., Johnson, D. C., Weinhold, N., Goldschmidt, H., Landgren, O., Lynch, H. T., Hemminki, K., & Houlston, R. S. (2013) · Leukemia · doi:10.1038/leu.2013.344 · Cited by 94
Go, R. S., Gundrum, J. D., & Neuner, J. M. (2014) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2014.09.004 · Cited by 87
Spectrum of manifestations of monoclonal gammopathy-associated renal lesions
Sethi, S. M., Fervenza, F. C., & Rajkumar, S. V. (2016) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000201 · Cited by 84
“0000000000000201 Monoclonal gammopathies consist of a heterogeneous group of disorders characterized by clonal proliferation of immunoglobulin producing B-lymphocytes or plasma cell clone [1,2].”
BackgroundSelf-citationBianchi, G., Kyle, R. A., Colby, C. L., Larson, D. R., Kumar, S. K., Katzmann, J. A., Dispenzieri, A. A., Therneau, T. M., Cerhan, J. R., Melton, L. J., et al. (2010) · Blood · doi:10.1182/blood-2010-04-277566 · Cited by 86
“Severe anemia/pancytopenia 6 (17) 2 (29) .”
Self-citationChang, S., Luo, S., O’Brian, K., Thomas, T. S., Colditz, G. A., Carlsson, N. P., & Carson, K. R. (2015) · The Lancet Haematology · doi:10.1016/s2352-3026(14)00037-4 · Cited by 81
The Clinical Picture of Severe Systemic Capillary-Leak Syndrome Episodes Requiring ICU Admission
de Chambrun, M. P., Luyt, C. E., Beloncle, F., Gousseff, M., Mauhin, W., Argaud, L., Ledochowski, S., Moreau, A., Sonneville, R., Verdière, B., et al. (2017) · Critical Care Medicine · doi:10.1097/ccm.0000000000002496 · Cited by 80
“Furthermore, a mean age around 50 years agrees with the natural epidemiology of monoclonal gammopathy, whose index first flare occurs during the fifth decade (16, 17).”
BackgroundHarousseau, J., Shaughnessy, J. D., & Richardson, P. G. G. (2004) · Hematology · doi:10.1182/asheducation-2004.1.237 · Cited by 106
The Clinical Spectrum of IgM-Related Amyloidosis
Terrier, B., Jaccard, A., Harousseau, J., Delarue, R., Tournilhac, O., Hunault, M., Hamidou, M. A., Dantal, J., Bernard, M., Grosbois, B., et al. (2008) · Medicine · doi:10.1097/md.0b13e31816c43b6 · Cited by 79
Þórðardóttir, M., Lindqvist, E. K., Lund, S. H., Costello, R., Burton, D., Korde, N., Mailankody, S., Eiríksdóttir, G., Launer, L. J., Gudnason, V. G., et al. (2017) · Blood Advances · doi:10.1182/bloodadvances.2017007609 · Cited by 80
Bochtler, T., Hegenbart, U., Heiß, C., Benner, A., Moos, M., Seckinger, A., Pschowski-Zuck, S., Kirn, D., Neben, K., Bartram, C. R., et al. (2011) · Blood · doi:10.1182/blood-2010-02-268987 · Cited by 80
Ng, A. C., Khosla, S., Charatcharoenwitthaya, N., Kumar, S. K., Achenbach, S. J., Holets, M. F., McCready, L. K., Melton, L. J., Kyle, R. A., Rajkumar, S. V., et al. (2011) · Blood · doi:10.1182/blood-2011-04-351437 · Cited by 75
“Furthermore, our findings demonstrate that (1) the increased incidence of fractures previously found to occur in patients with MGUS may not be reflected in aBMD measurements by DXA that were relatively insensitive compared with HRpQCT for measuring bone loss in MGUS; (2) patients with MGUS have skeletal microstructura…”
BackgroundMethodResultSelf-citationKyle, R. A., & Rajkumar, S. V. (2011) · PubMed · Cited by 91
Self-citationScreening panels for monoclonal gammopathies: time to change.
Katzmann, J. A. (2009) · PubMed · Cited by 101
Marinac, C. R., Birmann, B. M., Lee, I.-M. M., ROSNER, B. A., Townsend, M. K., Giovannucci, E. L., Rebbeck, T. R., Buring, J. E., & Colditz, G. A. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0010-4 · Cited by 78
“MM is preceded by an asymptomatic premalignant condition known as monoclonal gammopathy of undetermined significance (MGUS), 3 and individuals with MGUS have a risk of progression to MM of ~1–2% per year.(4) MM is expected to account for >32,800 new cancer diagnoses and >12,500 cancer deaths in the United States (US)…”
Backgroundon behalf of the Heinz Nixdorf Recall Study Investigative Group, Eisele, L., Dürig, J., Hüttmann, A., Dührsen, U., Assert, R., Bokhof, B., Erbel, R. M., Mann, K., Jöckel, K., et al. (2011) · Annals of Hematology · doi:10.1007/s00277-011-1293-1 · Cited by 82
“Long-term follow-up studies of MGUS cases demonstrated an average risk of 1%/year of developing multiple myeloma (MM) or a related lymphoproliferative malignancy [3, 4].”
BackgroundSerum-free light-chain assay: clinical utility and limitations
Bhole, M. V., Sadler, R., & Ramasamy, K. (2014) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1177/0004563213518758 · Cited by 80
Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma
Kyle, R. A., Miguel, J. F. S., Mateos, M., & Rajkumar, S. V. (2014) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2014.06.005 · Cited by 81
Self-citationAnguiano, A., Tuchman, S. A., Acharya, C. R., Salter, K. H., Gasparetto, C., Zhan, F., Dhodapkar, M. V., Nevins, J. R., Barlogie, B., Shaughnessy, J. D., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.1916 · Cited by 78
“Much of the published work regarding GEP of both MGUS and MM has met this limitation5,14,24-31,33,34; our MGUS data embody no exception because they contains less than 5 years of follow-up and relatively few transformations to MM.”
BackgroundInfluentialCurrent applications of multiparameter flow cytometry in plasma cell disorders
Jelínek, T., Bezděková, R., Zátopková, M., Burgos, L., Šimíček, M., Ševčíková, T., Paiva, B., & Hájek, R. (2017) · Blood Cancer Journal · doi:10.1038/bcj.2017.90 · Cited by 78
Cancer incidence in Canada: trends and projections (1983–2032)
Xie, L., Semenciw, R. M., & Mery, L. (2015) · Health Promotion and Chronic Disease Prevention in Canada · doi:10.24095/hpcdp.35.s1.02 · Cited by 96
The Microenvironment and Molecular Biology of the Multiple Myeloma Tumor
Lemaire, M., Deleu, S., Bruyne, E. D., Valckenborgh, E. V., Menu, E., & Vanderkerken, K. (2011) · Advances in cancer research · doi:10.1016/b978-0-12-386469-7.00002-5 · Cited by 80
Monoclonal gammopathy: The good, the bad and the ugly
Glavey, S. V., & Leung, N. (2015) · Blood Reviews · doi:10.1016/j.blre.2015.12.001 · Cited by 72
Rajkumar, S. V. (2009) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2009.01.001 · Cited by 94
Self-citationRajkumar, S. V., Kyle, R. A., Therneau, T. M., Clark, R. J., Bradwell, A. R., Melton, L. J., Larson, D. R., Plevak, M. F., & Katzmann, J. A. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05169.x · Cited by 71
“…light chains in the serum predicts risk of progression in monoclonal gammopathy of undetermined significance Monoclonal gammopathy of undetermined significance (MGUS) is a premalignant condition that leads to multiple myeloma (MM) or related malignancy at the rate of 1% per year (Kyle et al, 2002).”
BackgroundSelf-citationPractical Considerations for the Measurement of Free Light Chains in Serum
Tate, J. R., Gill, D. S., Cobcroft, R., & Hickman, P. E. (2003) · Clinical Chemistry · doi:10.1373/49.8.1252 · Cited by 71
“In MGUS patients, the K/L FLC ratio and concentration may be within population reference intervals despite the presence of monoclonal intact immunoglobulin concentrations 30 g/L in serum ( 18 ).”
BackgroundMcShane, C. M., Murray, L., Landgren, O., O’Rorke, M. A., Korde, N., Kunzmann, A. T., Ismail, M. R., & Anderson, L. A. (2014) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-13-0695 · Cited by 71
“progression to multiple myeloma or other lymphoproliferative disorders (5).”
BackgroundWillrich, M. A. V., Murray, D. L., & Kyle, R. A. (2017) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2017.05.001 · Cited by 78
Self-citationSeidl, S., Ackermann, J., Kaufmann, H., Keck, A. V., Nösslinger, T., Zielinski, C. C., Drach, J. W., & Zöchbauer‐Müller, S. (2004) · Cancer · doi:10.1002/cncr.20295 · Cited by 70
“MGUS cells secrete monoclonal immunoglobulin and progress to malignant MM at a rate of 1% per year.(2) According to reported experience over the past decades, MM comprises various entities with a heterogeneous clinical course, ranging from a relatively benign disorder to a 2598”
BackgroundDiagnostic and therapeutic approach of systemic amyloidosis.
Hazenberg, B. P. C., Gameren, I. I. V., Bijzet, J., Jager, P. L., & van Rijswijk, M. H. (2004) · PubMed · Cited by 69
Martin, W., Abraham, R. S., Shanafelt, T. D., Clark, R. J., Bone, N. D., Geyer, S. M., Katzmann, J. A., Bradwell, A. R., Kay, N. E., & Witzig, T. E. (2007) · Translational research · doi:10.1016/j.trsl.2006.11.001 · Cited by 69
Serum free light chain assessment in monoclonal gammopathy and kidney disease
Hutchison, C. A., Basnayake, K., & Cockwell, P. (2009) · Nature Reviews Nephrology · doi:10.1038/nrneph.2009.151 · Cited by 74
“More recently, serum FLCs were shown to be an independent risk factor for progression of MGUS in a study carried out by the Mayo Clinic”
BackgroundHillengaß, J., Weber, M., Kilk, K., Listl, K., Wagner, B., Hillengaß, M., Hielscher, T., Farid, A., Neben, K., Delorme, S., et al. (2013) · Leukemia · doi:10.1038/leu.2013.244 · Cited by 68
Preleukemia: one name, many meanings
Koeffler, H. P., & Leong, G. X. Y. (2016) · Leukemia · doi:10.1038/leu.2016.364 · Cited by 72
Microarray‐based understanding of normal and malignant plasma cells
Vos, J. D., Hose, D., Reme, T. X., Tarte, K., Moreaux, J., Mahtouk, K., Jourdan, M., Goldschmidt, H., Rossi, J., Cremer, F. W., et al. (2006) · Immunological Reviews · doi:10.1111/j.0105-2896.2006.00362.x · Cited by 73
“MGUS is frequent in the elderly, about 3% of the individuals over 70 years old (65).”
BackgroundDNA methylation of microRNA genes in multiple myeloma
Wong, K. Y., Huang, X., & Chim, C. S. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs212 · Cited by 69
“MGUS progresses to symptomatic MM at a rate of 1% per year, and hence is considered as the precursor of MM (3).”
BackgroundEvolving diagnostic criteria for multiple myeloma
Rajkumar, S. V. (2015) · Hematology · doi:10.1182/asheducation-2015.1.272 · Cited by 72
Self-citationSecondary antibody deficiencies
Dhalla, F., & Misbah, S. (2015) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0000000000000215 · Cited by 68
Evolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression
de Larrea, C. F., Isola, I., Pereira, A., Cibeira, M. T., Magnano, L., Tovar, N., Rodríguez‐Lobato, L. G., Calvo, X., Aróstegui, J. I., Díaz, T., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0013-4 · Cited by 71
Pineda‐Roman, M., Bolejack, V., Arzoumanian, V., Anaissie, E., Van Rhee, F., Zangari, M., Walker, R., Hollmig, K., Shaughnessy, J. D., Epstein, J., et al. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06441.x · Cited by 66
“Monoclonal gammopathy of undetermined significance progresses to symptomatic MM at a low annual rate of about 1Æ5% (Kyle et al, 2002), although it is unclear whether all MM evolve from MGUS (Bataille & Harousseau, 1997).”
BackgroundSack, F., Kristen, A. V., Goldschmidt, H., Schnabel, P. A., Dengler, T. J., Koch, A., & Karck, M. (2007) · European Journal of Cardio-Thoracic Surgery · doi:10.1016/j.ejcts.2007.10.025 · Cited by 65
van de Donk, N. W. C. J., Mutis, T., Poddighe, P. J., Lokhorst, H. M., & Zweegman, S. (2016) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.12504 · Cited by 74
“Progression of MGUS to MM or other related malignancies occurs at a rate of approximately 1% per year [12, 25, 26].”
BackgroundEpidemiology and outcomes research for MGUS, myeloma and amyloidosis
Sirohi, B., & Powles, R. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.01.065 · Cited by 74
Neurological manifestations of Waldenström macroglobulinemia
Baehring, J. M., Hochberg, E. P., Raje, N. S., Ulrickson, M. L., & Hochberg, F. H. (2008) · Nature Clinical Practice Neurology · doi:10.1038/ncpneuro0917 · Cited by 64
Gourzones-Dmitriev, C., Kassambara, A., Sahota, S., Rème, T., Moreaux, J., Bourquard, P., Hose, D., Pasero, P., Constantinou, A., & Klein, B. (2013) · Cell Cycle · doi:10.4161/cc.25951 · Cited by 61
The Immune Microenvironment of Myeloma
Noonan, K. A., & Borrello, I. (2011) · Cancer Microenvironment · doi:10.1007/s12307-011-0086-3 · Cited by 68
Shephard, E. A., Neal, R. D., Rose, P. W., Walter, F. M., Litt, E., & Hamilton, W. T. (2015) · British Journal of General Practice · doi:10.3399/bjgp15x683545 · Cited by 65
Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma
Kyle, R. A., & Rajkumar, S. V. (2010) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-010-0047-9 · Cited by 61
“5 g/dL had a 49% risk of progression [17].”
BackgroundResultInfluentialSelf-citationMultiple myeloma – an update on diagnosis and treatment
Caers, J., Broek, I. V., Raeve, H. D., Michaux, L., Trullemans, F., Schots, R., Camp, B. V., & Vanderkerken, K. (2008) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2008.01127.x · Cited by 75
Herrera, G. A. (2009) · Archives of Pathology & Laboratory Medicine · doi:10.5858/133.2.249 · Cited by 63
Hogan, J. J., & Weiss, B. M. (2016) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.03160316 · Cited by 68
Kohlhagen, M., Barnidge, D. R., Mills, J. R., Stoner, J., Gurtner, K. M., Liptac, A. M., Lofgren, D. I., Vanderboom, P. M., Dispenzieri, A. A., Katzmann, J. A., et al. (2016) · Clinical Chemistry · doi:10.1373/clinchem.2015.253781 · Cited by 62
HIV-Associated Monoclonal Gammopathy: A Retrospective Analysis of 25 Patients
Amara, S., Dezube, B. J., Cooley, T. P., Pantanowitz, L., & Aboulafia, D. M. (2006) · Clinical Infectious Diseases · doi:10.1086/508351 · Cited by 64
“and primary amyloidosis [1, 2].”
BackgroundInfluentialBone marrow microenvironment in myelomagenesis: its potential role in early diagnosis
Balakumaran, A., Robey, P. G., Fedarko, N. S., & Landgren, O. (2010) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.10.31 · Cited by 70
“Although it has been known for decades that individuals diagnosed with the asymptomatic condition, monoclonal gammopathy of undetermined significance (MGUS), on average, have a 1% annual risk of developing MM [4], until recently, it has not been known whether all MM cases are preceded by a premalignant stage (MGUS).”
BackgroundEpidemiology, genetics and treatment of multiple myeloma and precursor diseases
Hemminki, K., Försti, A., Houlston, R. S., & Sud, A. (2021) · International Journal of Cancer · doi:10.1002/ijc.33762 · Cited by 70
Distinguishing primary and secondary translocations in multiple myeloma
Gabrea, A., Bergsagel, P. L., & Kuehl, W. M. (2006) · DNA repair · doi:10.1016/j.dnarep.2006.05.012 · Cited by 65
Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma
Rajkumar, S. V., Lacy, M. Q., & Kyle, R. A. (2007) · Blood Reviews · doi:10.1016/j.blre.2007.01.002 · Cited by 65
Self-citationAbraham, R. S., Ballman, K. V., Dispenzieri, A. A., Grill, D. E., Manske, M. K., Price-Troska, T. L., Gonzalez-Paz, N. C., Gertz, M. A., & Fonseca, R. (2004) · Blood · doi:10.1182/blood-2004-04-1424 · Cited by 66
Anderson, K. C., Shaughnessy, J. D., Barlogie, B., Harousseau, J., & Roodman, G. D. (2002) · Hematology · doi:10.1182/asheducation-2002.1.214 · Cited by 71
Metformin and Cancer, an Ambiguanidous Relationship
Skuli, S. J., Alomari, S., Gaitsch, H., Bakayoko, A., Skuli, N., & Tyler, B. (2022) · Pharmaceuticals · doi:10.3390/ph15050626 · Cited by 65
“The current risk of progression to MM is 1% per year in MGUS patients [85].”
BackgroundObesity and multiple myeloma: Emerging mechanisms and perspectives
Tentolouris, A., Ntanasis‐Stathopoulos, I., & Terpos, E. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.04.003 · Cited by 63
DNA Methylation Profiles of Lymphoid and Hematopoietic Malignancies
Takahashi, T., Shivapurkar, N., Reddy, J., Shigematsu, H., Miyajima, K., Suzuki, M., Toyooka, S., Zöchbauer‐Müller, S., Drach, J. W., Parikh, G. Y., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0716 · Cited by 60
“The risk of progression of MGUS to MM or related disorders has been reported to be about 1%/year (3) or higher (4, 5).”
BackgroundRetractedOncogenomics to Target Myeloma in the Bone Marrow Microenvironment
Anderson, K. C. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3366 · Cited by 60
“Kyle has carefully followed individuals with MGUS and identified clinical features predicting for progression (60), it has only recently been appreciated that all MM patients likely go through this precursor MGUS stage (61, 62).”
BackgroundPiehler, A. P., Gulbrandsen, N., Kierulf, P., & Urdal, P. (2008) · Clinical Chemistry · doi:10.1373/clinchem.2008.106153 · Cited by 59
“Owing to lack of IFE results, it may also be that some patients with MGUS and low concentrations of monoclonal immunoglobulin in serum were missed in our screeningprocess.However,itiswelldocumentedthat MGUS patients with low concentrations of monoclonalimmunoglobulinhavealowerriskofprogressingto malignancy ( 20 ).”
BackgroundMonoclonal Gammopathy of Undetermined Significance
Kyle, R. A., & Rajkumar, S. V. (2005) · Clinical Lymphoma & Myeloma · doi:10.3816/clm.2005.n.036 · Cited by 64
Self-citationTete, S. M., Bijl, M., Sahota, S. S., & Bos, N. A. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00257 · Cited by 62
“Circulating abnormal plasma cells can be detected in up to 20% of MGUS patients (102, 103) and up to 80% MM (107, 108).”
BackgroundKhan, R., Dhodapkar, M., Rosenthal, A., Heuck, C., Papanikolaou, X., Qu, P., van Rhee, F., Zangari, M., Jethava, Y., Epstein, J., et al. (2015) · Haematologica · doi:10.3324/haematol.2015.124651 · Cited by 56
“MGUS is essentially a benign clinical condition with an annual risk of approximately 1% of transformation into MM.(4) In comparison to MGUS, SMM has a greater risk of progression to MM with approximately 10% of patients progressing to MM each year for the first 5 years, after which the progression rate is more similar…”
BackgroundTomi, A.-L., Belkhir, R., Nocturne, G., Desmoulins, F., Berge, E., Pavy, S., Miceli‐Richard, C., Mariette, X., & Séror, R. (2015) · Arthritis & Rheumatology · doi:10.1002/art.39534 · Cited by 58
“0) (7), resulting in an 8% prevalence of MHD in patients with MG, which is much lower than what we observed in our primary SS patients (38%).”
ResultLong-term follow-up of IgM monoclonal gammopathy of undetermined significance
Kyle, R. A., Therneau, T. M., Rajkumar, S. V., Offord, J. R., Larson, D. R., Plevak, M. F., & Melton, L. J. (2003) · Seminars in Oncology · doi:10.1053/sonc.2003.50062 · Cited by 58
Self-citationGonsalves, W. I., Ramakrishnan, V., Hitosugi, T., Ghosh, T., Jevremovic, D., Dutta, T., Sakrikar, D., Petterson, X.-M., Wellik, L., Kumar, S. K., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.94543 · Cited by 57
“MGUS progresses to MM at a rate of 1% per year (24), whereas SMM has a much higher rate of progression of 10% per year for the first 5 years, 3% per year for the next 5 years, and then 1% per year thereafter (25).”
BackgroundRoeker, L. E., Larson, D. R., Kyle, R. A., Kumar, S. K., Dispenzieri, A. A., & Rajkumar, S. V. (2013) · Leukemia · doi:10.1038/leu.2013.34 · Cited by 57
Self-citationNext-Generation Sequencing for Clinical Management of Multiple Myeloma: Ready for Prime Time?
Bolli, N., Genuardi, E., Ziccheddu, B., Martello, M., Oliva, S., & Terragna, C. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00189 · Cited by 63
“MGUS is a stable condition and progresses at a low rate of 1%/year (2).”
BackgroundGhobrial, I. M., & Witzig, T. E. (2004) · Current Treatment Options in Oncology · doi:10.1007/s11864-004-0015-5 · Cited by 57
Hillengaß, J., Zechmann, C. M., Bäuerle, T., Wagner, B., Heiß, C., Benner, A., Ho, A. D., Neben, K., Hose, D., Kauczor, H., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2310 · Cited by 56
Metadata
- Authors
- Kyle, R. A., Therneau, T. M., Rajkumar, S. V., Offord, J. R., Larson, D. R., Plevak, M. F., & Melton, L. J.
- Affiliations
- Mayo Clinic (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2002-02-21
- Volume
- 346
- Issue
- 8
- Pages
- 564-569
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2000655497
- Cited by
- 1,475
- References
- 17
- Citations by year
- 2026: 32 · 2025: 51 · 2024: 66 · 2023: 48 · 2022: 62 · 2021: 65 · 2020: 66 · 2019: 56 · 2018: 67 · 2017: 62 · 2016: 59 · 2015: 63 · 2014: 74 · 2013: 87 · 2012: 63
- FWCI
- 23.95
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (CA6 2242, P01CA062242)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Internal Medicine › Amyloidosis: Diagnosis, Treatment, Outcomes
- Keywords
- monoclonal gammopathy of undetermined significance, progression to multiple myeloma, prognosis, plasma cell neoplasms, AL amyloidosis, macroglobulinemia, chronic lymphocytic leukemia, plasmacytoma, smoldering multiple myeloma, bone marrow plasma cells, risk prediction
- MeSH terms
- Adult, Aged, Amyloidosis, Follow-Up Studies, Humans, Leukemia, Lymphoid, Lymphoma, Waldenstrom Macroglobulinemia, Middle Aged, Multiple Myeloma, Paraproteinemias, Probability, Prognosis, Risk Factors, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.